Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Completed · Phase 3

Conditions studied: Paroxysmal Nocturnal Hemoglobinuria

In brief

Evaluation of the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria

Key facts

Study ID

NCT03500549

Run by

Apellis Pharmaceuticals, Inc.

People needed

80

Starts

2018-06-14

Expected to finish

2020-08-13

Last updated by the study team

2022-03-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age
• Primary diagnosis of PNH confirmed by high-sensitivity flow cytometry
• On treatment with eculizumab. Dose of eculizumab must have been stable for at least 3 months prior to the Screening Visit
• Hb <10.5 g/dL at the Screening Visit
• Absolute reticulocyte count > 1.0x ULN at the Screening Visit
• Platelet count of >50,000/mm3 at the Screening Visit
• Absolute neutrophil count >500/mm3 at the Screening Visit
• Vaccination against Neisseria meningitides types A, C, W, Y and B, Streptococcus pneumoniae and Haemophilus influenzae Type B (Hib) either within 2 years prior to Day 1 dosing, or within 14 days after starting treatment with APL-2. Unless documented evidence exists that subjects are non-responders to vaccination as evidenced by titers or display titer levels within acceptable local limits
• Women of child-bearing potential (WOCBP) must have a negative pregnancy test at the Screening and Day -28 Visit (Run-in Period) and must agree to use protocol defined methods of contraception for the duration of the study and 90 days after their last dose of study drug
• Males must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study and 90 days after their last dose of study drug
• Willing and able to give informed consent
• Willing and able to self-administer APL-2 (administration by caregiver will be allowed)
• Have a body mass index (BMI) ≤35.0 kg/m2

You may not qualify if…

• Active bacterial infection that has not resolved within 14 week of Day -28 (first dose of APL-2)
• Receiving iron, folic acid, vitamin B12 and EPO, unless the dose is stable, in the 4 weeks prior to Screening
• Hereditary complement deficiency
• History of bone marrow transplantation
• History or presence of hypersensitivity or idiosyncratic reaction to compounds related to the investigational product or SC administration
• Participation in any other investigational drug trial or exposure to other investigational agent within 30 days or 5 half-lives (whichever is longer)
• Currently breast-feeding women
• Inability to cooperate or any condition that, in the opinion of the investigator, could increase the subject's risk of participating in the study or confound the outcome of the study
• This study includes cardiac safety evaluations. The following cardiac eligibility criteria are necessary to avoid confounding the cardiac safety outcomes:
• History or family history of Long QT Syndrome or torsade de pointes, unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden death
• Myocardial infarction, CABG, coronary or cerebral artery stenting and /or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months or greater than Class 2 Angina Pectoris or NYHA Heart Failure Class >2
• QTcF > 470 ms, PR > 280 ms
• Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities
• Receiving Class 1 or Class 3 antiarrhythmic agents, or arsenic, methadone, ondansetron or pentamidine at screening
• Receiving any other QTc-prolonging drugs (see Appendix 4 in Section 19.4), at a stable dose for less than 3 weeks prior to dosing
• Receiving prophylactic ciprofloxacin, erythromycin or azithromycin for less than one week prior to the first dose of study medication (must have a repeat screening ECG after one week of prophylactic antibiotics with QTcF < 470 ms)

Where it is running

• Sarcoma Oncology Research Center — Santa Monica, California, United States
• Denver Health — Denver, Colorado, United States
• Georgetown University Hospital — Washington D.C., District of Columbia, United States
• Cancer Specialists of North Florida — Jacksonville, Florida, United States
• Lakes Research — Miami Lakes, Florida, United States
• Mid Florida Hematology and Oncology — Orange City, Florida, United States
• Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
• Northwestern University — Chicago, Illinois, United States
• Investigative Clinical Research of Indiana — Indianapolis, Indiana, United States
• Cancer & Hematology Centers of Western Michigan — Grand Rapids, Michigan, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• New York Cancer & Blood Specialists — East Setauket, New York, United States
• New York Cancer & Blood Specialists — The Bronx, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Good Samaritan Hospital — Corvallis, Oregon, United States
• University of Tennessee Medical Center — Knoxville, Tennessee, United States
• Baptist Cancer Center — Memphis, Tennessee, United States
• HOPE Cancer Center of East Texas — Tyler, Texas, United States
• Royal Melbourne Hospital — Melbourne, Victoria, Australia
• Cliniques Universitaires Saint-Luc — Woluwe-Saint-Lambert, Vlaams-Brabant, Belgium
• AZ Delta Campus Wilgenstraat — Roeselare, West-Vlaanderen, Belgium
• University of Alberta — Edmonton, Alberta, Canada
• Toronto General Hospital — Toronto, Ontario, Canada
• Centre Hospitalier Annecy Genevois — Annecy, France
• University of Southern California — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.